ANKRD26-related thrombocytopenia 2 with a baseline increase in blasts: implications for clinical surveillance
Abstract
Abstract We report on 8 patients with ankyrin repeat domain 26 (ANKRD26)–related thrombocytopenia 2 (ANKRD26-RT) with elevated bone marrow myeloblasts and dysmegakaryopoiesis, without somatic genetic abnormalities or progression to malignancy during long-term observation, findings which may constitute inherent ANKRD26-RT biology rather than progression to myeloid malignancy.
Article Details
Authors (17)
Lara Wahlster
1Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
Lucy A. Godley
Jason X. Cheng
3Department of Pathology, The University of Chicago, Chicago, IL
Michael W. Drazer
4Sections of Hematology/Oncology and Genetic Medicine, Department of Medicine, The University of Chicago Comprehensive Cancer Center, Chicago, IL
Christopher R. Reilly
Geraldine S. Pinkus
6Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Jared H. Rowe
1Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Nina Weichert-Leahey
1Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
R. Grant Rowe
Department of Hematology, Boston Children’s Hospital
Lev Gorfinkel
1Boston Children's Hospital, Department of Pediatrics, Boston, United States
Karyn Brundige
1Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Franziska Wachter
1Dana-Farber Cancer Institute, Boston, United States
Luana Messa
1Division of Hematology/Oncology, Boston Children's Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States
Alan D. Michelson
1Division of Hematology/Oncology, Boston Children’s Hospital, and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Alan B. Cantor
Akiko Shimamura
Dana Farber/Boston Children's Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
Jacob R. Bledsoe